JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB124001

Native Clostridium difficile Toxin B protein

5

(1 Review)

|

(9 Publications)

Native Clostridium difficile Toxin B protein is a Clostridium difficile (strain VPI10463) Full Length protein in the 2 to 2366 aa range with >95% purity and suitable for SDS-PAGE and Functional studies. The predicted molecular weight of ab124001 native protein is 270 kDa.

- Save time and ensure accurate results - use our Clostridium difficile Toxin B as a control
- Optimal protein bioactivity and stability

View Alternative Names

toxB, tcdB, Toxin B

1 Images
SDS-PAGE - Native Clostridium difficile Toxin B protein (AB124001)
  • SDS-PAGE

Unknown

SDS-PAGE - Native Clostridium difficile Toxin B protein (AB124001)

SDS-PAGE showing ab124001 at 270 kDa.

Key facts

Purity

>95%

Expression system

Native

Tags

Tag free

Applications

SDS-PAGE, FuncS

applications

Biologically active

Yes

Biological activity

Measured by vercytotoxicity assay with 2 pg/ml as lowest point at which rounded cells are observed.

Accession

P18177

Animal free

No

Carrier free

No

Species

Clostridium difficile

Reconstitution

Reconstitute in 250 µL of water

Storage buffer

pH: 7 - 8 Constituents: 92% Clostridium difficile Toxin B, 5% Sucrose, 1.19% HEPES, 0.88% Sodium chloride

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "FuncS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

The Native Clostridium difficile Toxin B protein ab124001 is derived from a pathogenic organism, and may be involved in a disease process, consequently exposure may have adverse health effects.

This product is an active protein and may elicit a biological response in vivo, handle with caution.

Ensure the validity of your result using our native Clostridium difficile Toxin B protein ab124001 as a positive control in SDS-PAGE.

Check out our protein gel staining guide for SDS-PAGE here

Functional Studies Protocol
1.1 Vero cells are plated out the night before on a 96-well plate at a concentration of 20K cells per well (in 100 ml), then incubated at 37°C, 5% CO2. The following day they should be lightly confluent.
1.2 Lyophilised toxin/toxoid is resuspended as per the instructions in the certificate of analysis, and diluted in duplicate to 0.1 mg/ml in DMEM (200 ml total) without FBS in the first well of a non-TC-treated 96-well plate. A serial 5-fold dilution is performed (40µl in 160 µl) in the same media using a multichannel for 11 dilutions in total, leaving the 12th dilution as a media control.
1.3 20 µl of each dilution is then pipetted onto each well of the pre-prepared Vero cells and then incubated at 37°C, 5% CO2 for 24 hours.
1.4 The following day, the cells are examined using an inverted phase contrast tissue culture microscope. Cells with active toxin on should be rounded, cells without significant toxicity should look like the control cells.

Sequence info

[{"sequence":"","proteinLength":"Full Length","predictedMolecularWeight":"270 kDa","actualMolecularWeight":null,"aminoAcidEnd":2366,"aminoAcidStart":2,"nature":"Native","expressionSystem":null,"accessionNumber":"P18177","tags":[]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Avoid freeze / thaw cycle
True

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Clostridium difficile Toxin B also known as CD Toxin B or B protein is a potent toxin produced by the bacterium Clostridium difficile. It is one of the major virulence factors alongside Toxin A. This protein carries significant weight approximately 270 kDa. It is expressed in the intestinal tract when Clostridium difficile colonizes and proliferates often leading to severe gastrointestinal conditions. The presence of toxins including both Toxin A and Toxin B contributes to the pathogenicity of C. diff infection.
Biological function summary

This toxin exerts its effects by modifying intracellular signaling pathways disrupting tight junctions and leading to cell apoptosis. Toxin B specifically targets the Rho family of GTPases through glucosylation leading to actin cytoskeleton disorganization and subsequent cell rounding and tissue damage. It functions independently but works in conjunction with Toxin A to enhance virulence. As part of its biological role Toxin B proves essential in the pathogenesis of diseases associated with C. diff infection.

Pathways

Research shows Toxin B's involvement in the disruption of the actin cytoskeleton pathway. This pathway alteration results from direct modification of small GTP-binding proteins such as RhoA Rac and Cdc42. Toxin B's activity leads to loss of cell structure and increased cell lysis showcasing how it fits into major cellular integrity pathways. Its interaction with these proteins places it alongside other microbial toxins that manipulate host cell signaling.

Toxin B has a strong association with Clostridium difficile infection (CDI) which often manifests as pseudomembranous colitis. CDI presents with symptoms such as severe diarrhea and colonic inflammation. Furthermore Toxin B contributes significantly to the disease severity in comparison to other microbial toxins. While Toxin A also plays a role studies suggest that Toxin B's impact on the intestinal epithelium is more severe marking it as a critical target for therapeutic intervention against CDI.

Specifications

Form

Lyophilized

Additional notes

Clostridium difficile Toxin B has been highly purified.

General info

Function

Toxin B. Precursor of a cytotoxin that targets and disrupts the colonic epithelium, inducing the host inflammatory and innate immune responses and resulting in diarrhea and pseudomembranous colitis (PubMed : 20844489, PubMed : 24919149). TcdB constitutes the main toxin that mediates the pathology of C.difficile infection, an opportunistic pathogen that colonizes the colon when the normal gut microbiome is disrupted (PubMed : 19252482, PubMed : 20844489). Compared to TcdA, TcdB is more virulent and more important for inducing the host inflammatory and innate immune responses (PubMed : 19252482, PubMed : 24919149). This form constitutes the precursor of the toxin : it enters into host cells and mediates autoprocessing to release the active toxin (Glucosyltransferase TcdB) into the host cytosol (PubMed : 10768933, PubMed : 11152463, PubMed : 12941936, PubMed : 17334356, PubMed : 20498856). Targets colonic epithelia by binding to the frizzled receptors FZD1, FZD2 and FZD7, and enters host cells via clathrin-mediated endocytosis (PubMed : 27680706). Frizzled receptors constitute the major host receptors in the colonic epithelium, but other receptors, such as CSPG4 or NECTIN3/PVRL3, have been identified (PubMed : 25547119, PubMed : 26038560, PubMed : 27680706). Binding to carbohydrates and sulfated glycosaminoglycans on host cell surface also contribute to entry into cells (By similarity). Once entered into host cells, acidification in the endosome promotes the membrane insertion of the translocation region and formation of a pore, leading to translocation of the GT44 and peptidase C80 domains across the endosomal membrane (PubMed : 11152463, PubMed : 12941936, PubMed : 24567384). This activates the peptidase C80 domain and autocatalytic processing, releasing the N-terminal part (Glucosyltransferase TcdB), which constitutes the active part of the toxin, in the cytosol (PubMed : 17334356, PubMed : 27571750).. Glucosyltransferase TcdB. Active form of the toxin, which is released into the host cytosol following autoprocessing and inactivates small GTPases (PubMed : 16157585, PubMed : 17901056, PubMed : 24905543, PubMed : 24919149, PubMed : 7777059, PubMed : 8144660). Acts by mediating monoglucosylation of small GTPases of the Rho family (Rac1, RhoA, RhoB, RhoC, RhoG and Cdc42) in host cells at the conserved threonine residue located in the switch I region ('Thr-37/35'), using UDP-alpha-D-glucose as the sugar donor (PubMed : 16157585, PubMed : 17901056, PubMed : 24905543, PubMed : 24919149, PubMed : 7777059). Monoglucosylation of host small GTPases completely prevents the recognition of the downstream effector, blocking the GTPases in their inactive form, leading to actin cytoskeleton disruption and cell death, resulting in the loss of colonic epithelial barrier function (PubMed : 24919149, PubMed : 7777059).

Sequence similarities

Belongs to the clostridial glucosylating toxin (LCGT) family.

Post-translational modifications

Toxin B. Undergoes autocatalytic cleavage to release the N-terminal part (Glucosyltransferase TcdB), which constitutes the active part of the toxin, in the host cytosol (PubMed:12941936, PubMed:17334356, PubMed:27571750). 1D-myo-inositol hexakisphosphate-binding (InsP6) activates the peptidase C80 domain and promotes autoprocessing (PubMed:17334356).

Subcellular localisation

Host endosome membrane

Product protocols

Target data

Toxin B. Precursor of a cytotoxin that targets and disrupts the colonic epithelium, inducing the host inflammatory and innate immune responses and resulting in diarrhea and pseudomembranous colitis (PubMed : 20844489, PubMed : 24919149). TcdB constitutes the main toxin that mediates the pathology of C.difficile infection, an opportunistic pathogen that colonizes the colon when the normal gut microbiome is disrupted (PubMed : 19252482, PubMed : 20844489). Compared to TcdA, TcdB is more virulent and more important for inducing the host inflammatory and innate immune responses (PubMed : 19252482, PubMed : 24919149). This form constitutes the precursor of the toxin : it enters into host cells and mediates autoprocessing to release the active toxin (Glucosyltransferase TcdB) into the host cytosol (PubMed : 10768933, PubMed : 11152463, PubMed : 12941936, PubMed : 17334356, PubMed : 20498856). Targets colonic epithelia by binding to the frizzled receptors FZD1, FZD2 and FZD7, and enters host cells via clathrin-mediated endocytosis (PubMed : 27680706). Frizzled receptors constitute the major host receptors in the colonic epithelium, but other receptors, such as CSPG4 or NECTIN3/PVRL3, have been identified (PubMed : 25547119, PubMed : 26038560, PubMed : 27680706). Binding to carbohydrates and sulfated glycosaminoglycans on host cell surface also contribute to entry into cells (By similarity). Once entered into host cells, acidification in the endosome promotes the membrane insertion of the translocation region and formation of a pore, leading to translocation of the GT44 and peptidase C80 domains across the endosomal membrane (PubMed : 11152463, PubMed : 12941936, PubMed : 24567384). This activates the peptidase C80 domain and autocatalytic processing, releasing the N-terminal part (Glucosyltransferase TcdB), which constitutes the active part of the toxin, in the cytosol (PubMed : 17334356, PubMed : 27571750).. Glucosyltransferase TcdB. Active form of the toxin, which is released into the host cytosol following autoprocessing and inactivates small GTPases (PubMed : 16157585, PubMed : 17901056, PubMed : 24905543, PubMed : 24919149, PubMed : 7777059, PubMed : 8144660). Acts by mediating monoglucosylation of small GTPases of the Rho family (Rac1, RhoA, RhoB, RhoC, RhoG and Cdc42) in host cells at the conserved threonine residue located in the switch I region ('Thr-37/35'), using UDP-alpha-D-glucose as the sugar donor (PubMed : 16157585, PubMed : 17901056, PubMed : 24905543, PubMed : 24919149, PubMed : 7777059). Monoglucosylation of host small GTPases completely prevents the recognition of the downstream effector, blocking the GTPases in their inactive form, leading to actin cytoskeleton disruption and cell death, resulting in the loss of colonic epithelial barrier function (PubMed : 24919149, PubMed : 7777059).
See full target information tcdB

Publications (9)

Recent publications for all applications. Explore the full list and refine your search

Gut microbes 17:2506192 PubMed40383912

2025

CD44 is a macrophage receptor for TcdB from that its lysine-158 succinylation contributes to inflammation.

Applications

Unspecified application

Species

Unspecified reactive species

Zhuo Chen,Wenzi Zhang,Danni Wang,Ruiqin Luo,Yuexin Yao,Xiaoyang Tao,Lu Li,Qin Pan,Xiaoming Sun

Nature immunology 26:511-523 PubMed39930093

2025

Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants.

Applications

Unspecified application

Species

Unspecified reactive species

Shouya Feng,Matthew C Wierzbowski,Katja Hrovat-Schaale,Andreas Dumortier,Yaoyuan Zhang,Maria Zyulina,Paul J Baker,Thomas Reygaerts,Annemarie Steiner,Dominic De Nardo,Dhanya Lakshmi Narayanan,Florian Milhavet,Alberto Pinzon-Charry,Juan Ignacio Arostegui,Raju P Khubchandani,Matthias Geyer,Guilaine Boursier,Seth L Masters

Cell reports 41:111472 PubMed36223753

2022

Steroid hormone catabolites activate the pyrin inflammasome through a non-canonical mechanism.

Applications

Unspecified application

Species

Unspecified reactive species

Flora Magnotti,Daria Chirita,Sarah Dalmon,Amandine Martin,Pauline Bronnec,Jeremy Sousa,Olivier Helynck,Wonyong Lee,Daniel L Kastner,Jae Jin Chae,Michael F McDermott,Alexandre Belot,Michel Popoff,Pascal Sève,Sophie Georgin-Lavialle,Hélène Munier-Lehmann,Tu Anh Tran,Ellen De Langhe,Carine Wouters,Yvan Jamilloux,Thomas Henry

Methods in molecular biology (Clifton, N.J.) 2523:179-195 PubMed35759198

2022

Functional Assessment of Disease-Associated Pyrin Variants.

Applications

Unspecified application

Species

Unspecified reactive species

Daria Chirita,Yvan Jamilloux,Thomas Henry,Flora Magnotti

The Journal of experimental medicine 218: PubMed34342641

2021

ASC deglutathionylation is a checkpoint for NLRP3 inflammasome activation.

Applications

Unspecified application

Species

Unspecified reactive species

Shuhang Li,Linlin Wang,Zhihao Xu,Yuanyuan Huang,Rufeng Xue,Ting Yue,Linfeng Xu,Fanwu Gong,Shiyu Bai,Qielan Wu,Jiwei Liu,Bolong Lin,Huimin Zhang,Yanhong Xue,Pingyong Xu,Junjie Hou,Xiaofei Yang,Tengchuan Jin,Rongbin Zhou,Jizhong Lou,Tao Xu,Li Bai

EMBO molecular medicine 11:e10547 PubMed31589380

2019

Pyrin dephosphorylation is sufficient to trigger inflammasome activation in familial Mediterranean fever patients.

Applications

Unspecified application

Species

Unspecified reactive species

Flora Magnotti,Lucie Lefeuvre,Sarah Benezech,Tiphaine Malsot,Louis Waeckel,Amandine Martin,Sébastien Kerever,Daria Chirita,Marine Desjonqueres,Agnès Duquesne,Mathieu Gerfaud-Valentin,Audrey Laurent,Pascal Sève,Michel-Robert Popoff,Thierry Walzer,Alexandre Belot,Yvan Jamilloux,Thomas Henry

Infection and immunity 87: PubMed30530621

2018

Lectin Activity of the TcdA and TcdB Toxins of Clostridium difficile.

Applications

Unspecified application

Species

Unspecified reactive species

Lauren E Hartley-Tassell,Milena M Awad,Kate L Seib,Maria Scarselli,Silvana Savino,Joe Tiralongo,Dena Lyras,Christopher J Day,Michael P Jennings

Annals of the rheumatic diseases 76:2085-2094 PubMed28835462

2017

A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever.

Applications

Unspecified application

Species

Unspecified reactive species

Fiona Moghaddas,Rafael Llamas,Dominic De Nardo,Helios Martinez-Banaclocha,Juan J Martinez-Garcia,Pablo Mesa-Del-Castillo,Paul J Baker,Vanessa Gargallo,Anna Mensa-Vilaro,Scott Canna,Ian P Wicks,Pablo Pelegrin,Juan I Arostegui,Seth L Masters

Scientific reports 7:3665 PubMed28623367

2017

Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.

Applications

Neut

Species

Clostridium difficile

Melanie L Hutton,Bliss A Cunningham,Kate E Mackin,Shelley A Lyon,Meagan L James,Julian I Rood,Dena Lyras
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com